ELV250117P430000
- 64.01
- 0.000.00%
Elevance Health Newsroom
After experiencing a bumper harvest in 2024, the USA ETF may encounter setbacks this year.
The USA Exchange Traded Fund (ETF) received a record inflow of $1.1 trillion in 2024, but entering 2025, rapid growth may face more obstacles.
Investors in Elevance Health (NYSE:ELV) Have Seen Respectable Returns of 31% Over the Past Five Years
Elevance Health, Inc. (ELV): Among the Cheap Healthcare Stocks to Buy Heading Into 2025
Is Weakness In Elevance Health, Inc. (NYSE:ELV) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Today's Analyst Rating | Netflix Price Target Raised to $1000 by KeyBanc, Mizuho Securities Cuts Its Price Target Cut on Elevance Health to $455
Dec 24, Wall Street analysts have updated their stock ratings today including $Netflix(NFLX.US)$ and $Elevance Health(ELV.US)$.
Buckle up! Goldman Sachs: Market optimism is nearing its peak, Bullish on two defensive Sectors.
①Goldman Sachs advises investors to take more "defensive measures" as Wall Street's optimism about the USA economy and stock market approaches historical highs. ②Goldman Sachs' model is bullish on the performance of defensive stocks such as utilities and Medical Care.
Mizuho Securities Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $455
Mizuho Adjusts Price Target on Elevance Health to $455 From $505, Keeps Outperform Rating
Elevance Health Stock Plunges 29.6% in Q4: Buy, Hold or Sell?
U.S. Healthcare Spending Climbs 7.5% in 2023
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
25 U.S. 'Highest Conviction' Stocks – UBS
The Medical assistance program may come under pressure as Morgan Stanley downgrades Elevance Health (ELV.US).
Elevance Health (ELV.US) faces pressure in its Medical assistance Business, and Morgan Stanley downgraded the stock rating from "Shareholding" to "Hold" on Tuesday.
Elevance Downgraded at Morgan Stanley on Medicaid Headwinds
Health-care Sector Faces Mixed Prospects in 2025, Morgan Stanley Says
UnitedHealth, CVS Health Extend Decline as Pfizer CEO Cites Trump's PBM Comments
Morgan Stanley Downgrades Elevance Health(ELV.US) to Hold Rating, Cuts Target Price to $388
Morgan Stanley Sticks to Its Buy Rating for Elevance Health (ELV)
Worst Performing Stocks for Tax Loss Selling – Wolfe
The Return Trends At Elevance Health (NYSE:ELV) Look Promising